Shots:
- Bio-Thera and STADA have entered into an exclusive commercialization and license agreement for BAT2506, a biosimilar version of Simponi (golimumab)
- Under the collaboration, Bio-Thera is entitled to receive a $10M upfront and an additional $147.5M development and commercial milestones upon certain conditions fulfilment
- Furthermore, Bio-Thera will handle the development, manufacturing and supply activities of BAT2506, while STADA gains an exclusive right to commercialize it across the EU, UK, Switzerland and other selected regions
Ref: Stada| Image: Bio-Thera & Stada| Press Release
Related News:- Fresenius Reports the US FDA’s BLA Acceptance of FKS518 (Biosimilar, Denosumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
